Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (FRA:I54)

Market Cap	5.89B +487.4%
Revenue (ttm)	196.48M +52.5%
Net Income	36.53M +536.6%
EPS	0.09 +575.2%
Shares Out	n/a
PE Ratio	161.29
Forward PE	143.96
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	6.65
Previous Close	6.70
Day's Range	6.65 - 6.65
52-Week Range	2.34 - 7.70
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About FRA:I54

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides the customized gene editing services based on animals and cells to meet the needs of basic science research and drug development of the customers; provid...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 1,443
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: I54

Financial Performance

In 2025, FRA:I54's revenue was 1.38 billion, an increase of 40.63% compared to the previous year's 980.45 million. Earnings were 173.20 million, an increase of 416.37%.

Financial numbers in CNY

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 26, 2026

Data Sources Report a data error